BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Rilonacept: Completed Phase III enrollment

Regeneron disclosed in its 4Q10 earnings that it completed enrollment of about 240 patients in the double-blind, international Phase III PRE-SURGE 2 trial evaluating subcutaneous Arcalyst when given during the first 16 weeks of allopurinol therapy. Patients...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >